FTSE 100 news / Companies and sectors / AstraZeneca / Tezspire shows positive Phase 3 results in eosinophilic esophagitis
Tezspire shows positive Phase 3 results in eosinophilic esophagitis
+10.0 strongly positive
Amgen and AstraZeneca reported positive Phase 3 Tezspire results with 69% remission in EoE.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| TipRanks | 2 | +10.0 |
| AllSci | 1 | +10.0 |
| Reuters | 1 | +10.0 |
| The Pharma Letter | 1 | +10.0 |
| Benzinga | 1 | +10.0 |
| Investing.com Nigeria | 1 | +10.0 |
| Investing.com | 1 | +10.0 |
| Scrip | 1 | +10.0 |
| TradingView | 1 | +10.0 |
| Seeking Alpha | 1 | +10.0 |
| GuruFocus | 1 | +10.0 |
| Investing.com Canada | 1 | +10.0 |
| MarketScreener | 1 | +9.7 |
| Investing.com South Africa | 1 | +9.2 |
Day by day
Wednesday 21 October 2026
Amgen and AstraZeneca reported positive Phase 3 Tezspire results with 69% remission in EoE.
- +10.0 Amgen, AstraZeneca's Tezspire achieves 69% remission in Phase III EoE trial
69% remission in Phase III trial - +10.0 AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
69% remission in esophageal disease trial - +10.0 Amgen/AstraZeneca unveil strong Ph III results for Tezspire in EoE
Strong Phase III Tezspire results - +10.0 AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
Significant remission shown in EoE study - +10.0 Amgen, AstraZeneca report positive trial results for Tezspire in EoE By Investing.com
Positive Phase III Tezspire results - +10.0 Amgen, AstraZeneca report positive trial results for Tezspire in EoE
Positive Tezspire EoE trial results - +10.0 AstraZeneca reports full results from Phase 3 CROSSING trial of Tezspire
Full Phase 3 CROSSING results reported - +10.0 Amgen, AstraZeneca Detail Phase III Data For Tezspire’s Likely Third Indication
Phase III data for likely third Tezspire indication - +10.0 AstraZeneca Stocks Rise 2.7% as Tezspire Data Sharpen Expansion Case
Shares up 2.7% on Tezspire data - +10.0 Amgen, AstraZeneca report phase 3 results for Tezspire in eosinophilic esophagitis
Phase 3 EoE results reported - +10.0 Amgen (AMGN) and AstraZeneca Report Positive Phase 3 Trial Resul
Positive Phase 3 results reported - +10.0 AstraZeneca’s tezepelumab shows positive results for esophagitis By Investing.com
Positive esophagitis results for tezepelumab - +10.0 AstraZeneca, Amgen announce TEZSPIRE showed ‘significant’ improvements
Significant Tezspire improvements announced - +9.7 Amgen, AstraZeneca Say Tezspire Showed Improvement in Eosinophilic Esophagitis in Phase 3 Study
Tezspire improvement shown in Phase 3 - +9.2 Amgen and AstraZeneca report asthma drug trial results By Investing.com
Asthma drug trial results reported